MSD Animal Health brand pattern

Prevention begins with Protection

Protection begins with Bovilis®

Bovilis vaccines help farmers protect cattle from production losses and disease, giving them greater control of their herd’s health now and in the future.

Learn More

Learn more about our products

Filter products by disease

BVD Product

Bovilis® BVD

The only BVD vaccine with a 12 month fetal protection claim*

Learn more
MHIBR Product

Bovilis® MH+IBR

The only vaccine in New Zealand which helps control both MH and IBR, two of the most important pathogens associated with BRD

Learn more
RotavecCorona Product v2

Bovilis Rotavec® Corona

The only one shot scours vaccine for all classes of stock

Learn more
MHIBR Product

Bovilis® MH+IBR

The only vaccine in New Zealand which helps control both MH and IBR, two of the most important pathogens associated with BRD

Learn more
BVD Product

Bovilis® BVD

The only BVD vaccine with a 12 month fetal protection claim*

Learn more
RotavecCorona Product v2

Bovilis Rotavec® Corona

The only one shot scours vaccine for all classes of stock

Learn more
RotavecCorona Product v2

Bovilis Rotavec® Corona

The only one shot scours vaccine for all classes of stock

Learn more
RotavecCorona Product v2

Bovilis Rotavec® Corona

The only one shot scours vaccine for all classes of stock

Learn more
MHIBR Product

Bovilis® MH+IBR

The only vaccine in New Zealand which helps control both MH and IBR, two of the most important pathogens associated with BRD

Learn more
MHIBR Product

Bovilis® MH+IBR

The only vaccine in New Zealand which helps control both MH and IBR, two of the most important pathogens associated with BRD

Learn more
RotavecCorona Product v2

Bovilis Rotavec® Corona

The only one shot scours vaccine for all classes of stock

Learn more

Why vaccinate for BVD?

BVD is endemic in New Zealand, affecting both dairy and beef herds.

BVD has been estimated to cost the New Zealand cattle industry around $150 million a year.

LIC Data shows the prevalance of BVD in dairy herds is high1

  • 63% of dairy herds had a milk antibody level of >0.75
  • 13% of herds contained milking PI animals.

The situation in beef herds in New Zealand is similar.

  • In a comparative study2 of 94 low and high fertility beef herds, 65% were actively infected with BVD
  • A more recent study3 of 43 beef herds showed 58% had evidence of recent BVD infection.

Economic modelling shows it pays to control BVD.

Andrew Weir's economic model showed the various means of BVD control and how these reduced the impact of BVD compared to no control.

Weir A. PhD work submitted June 2016.

Andrew Weir's PhD work graph of economic model which shows economic return and cost saving of different BVD control measure combinations

Average discounted cost per year for an average 400 cow farm
* Only vaccinating milking heifers ** Calf vaccination then subsequent annual boosters until whole herd vaccination is achieved

Economic modelling showed it is always more cost effective to do something than to do nothing4.

Vaccination is a cost effective part of most control strategies.

Why Bovilis BVD?

The only BVD vaccine with a 12 month fetal protection claim*

Bovilis BVD is the only BVD vaccine with a 12 month fetal protection claim*

*Bovilis BVD provides 6 months fetal protection following the initial vaccination series (sensitiser and booster), and 12 months fetal protection following a third dose.

The key to BVD control is protecting the fetus to prevent PI calves being formed.

Flexible primary dosing interval

Bovilis BVD has a flexible primary dosing interval of 4 weeks to 6 months between the initial sensitiser and booster shots.

Illustration of Bovilis BVD primary dosing interval showing there can be an interval of 4 weeks to 6 months between sensitiser and booster vaccine shots

This extended vaccination interval allows farmers the convenience of aligning their vaccination schedule with other planned management practices.

Made from the strain which is the predominant subtype in NZ

Bovilis BVD is made with strain C86, a Type 1a BVD virus which is the predominant subtype in NZ5.

  • Australian isolates are predominantly subtype 1c6
  • The C86 strain and adjuvant in Bovilis BVD are highly immunogenic7,8
  • Bovilis BVD provides protection against diverse Type 1&2 BVD viruses, as well as Border Disease viruses7,8

Improves fertility in herds with active BVD infection

Vaccination with Bovilis BVD improves reproductive performance in herds with active BVD infection9

Table of trial results showing improved reproductive performance (pregnancy rate) in cattle vaccinated with Bovilis BVD versus controls

No drop in milk production

Vaccinating with Bovilis BVD doesn't cause a drop in milk production.

New Zealand dairy herds are vaccinated when milk production is near its peak, so its important that a vaccine has no effect on milk production.

A field study has demonstrated no observable difference between vaccinated and control animals following vaccination, and no effect on average milk yields.10

12 months duration of immunity for transient infection

Bovilis BVD provides 12 months duration of immunity for transient infection.11

While transiently infected animals are not the main source of BVD spread within a herd it is the most frequent infection type and the cost of lost production from a transiently infected animal is significant.

Safe for use in pregnant cattle

Bovilis BVD is formulated for safety in pregnant cows.

In breeding cattle it is good practice to administer the booster vaccination no less than, but close to 4 weeks before the planned start of mating to ensure fetal protection in early gestation. Bovilis BVD is safe for use in pregnant cows which provides confidence in situations when there is an extended mating period. If any cattle are pregnant at the time of vaccination there will be no adverse effects for the cow or her unborn calf.

What you need to know

References

* Following a third dose (annual vaccination) Bovilis BVD provides 12 months fetal protection.
1. Voges, H. and Hill, F. BVD Steering Committee Roadshow 2014
2. Heuer, C. et al. (2008). Effect of reproductive pathogens on pregnancy rates in beef herds. Proc. 38th Sem. Soc. Sheep and Beef Cattle Vets. NZVA; 141-147
3. Cuttance, W & Cuttance. (2014) E. Analysis of individual farm investigations into bovine viral diarrhoea in beef herds in the North Island of New Zealand. NZ Vet J. Nov; 62(6): 338-42
4. Weir A. PhD work submitted June 2016 

5. Horner GW et al. (2000) Typing of New Zealand strains of pestivirus. Surveillance 27(3):16

6. Mahony et al. (2005) Genetic analysis of bovine viral diarrhoea viruses from Australia. Veterinary Microbiology 106 1-6
7. Patel, J.R. et al. (2005) Variation in immunogenicity of ruminant pestiviruses as determined by the neutralisation assay, The Veterinary Journal, Vol 169, 468-472.
8. Makoschey, B et al. (2001) An inactivated bovine viral diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVD type 2.
9. Mawhinney, I., (2005) Vaccination with Bovilis BVD-MD improves fertility in dairy herds under field conditions. Tierärztliche Umschau 60(9):501-502
10. MSD Data on file
11. Munoz Bielsa, J. et al. Evaluation of the level of protection afforded by a BVD inactivated vaccine (C-86 strain), 12 months after vaccination. Journees Nationales des GTV, Nantes, 2005, 903

Why vaccinate for BRD?

Vaccination is an important risk management strategy to prevent BRD.

Bovine Respiratory Disease (BRD) is one of the most common and costly diseases of cattle globally. Due to the intensification of farming in New Zealand, BRD may now have a larger impact than what we have seen historically. Most cattle are susceptible to BRD at some point in their lifetime and it can impact performance.

Why Bovilis MH+IBR?

Proven performance

Since its launch in 2011, Bovilis MH+IBR has been used extensively in the Australian cattle industry where it has been shown to be extremely effective at reducing levels of respiratory disease morbidity and mortality.

In a large Australian feedlot trial1, cattle vaccinated with 2 doses of Bovilis MH+IBR had significantly lower morbidity and mortality rates due to BRD than control cattle vaccinated with other vaccines.

Bovilis MH+IBR Feedlot Trial Results

Click to enlarge

Flexible primary dosing interval

Bovilis MH+IBR has a flexible primary dosing interval of 2 weeks to 9 months between the initial sensitiser and booster shots.

This extended vaccination interval allows farmers the convenience of aligning their vaccination schedule with other planned management practices.

Immunity from 14 days following the 2nd dose

Bovilis MH+IBR vaccine provides active immunity 14 days after the 2nd dose.

For this reason vaccination should take place in advance of situations with high potential for BRD to occur. These situations may involve weaning, transport, mixing of cattle, weather extremes, dust, handling and change of diet.

Safe for use in pregnant cattle

Bovilis MH+IBR is formulated for safety in pregnant cattle.

This means farmers can confidently administer the vaccine to all stock types concurrently knowing there will be no adverse effects for the cow or her unborn calf.

What you need to know

References

1. Bovilis MH+IBR Field Trials: 2009:001. ISPAH Data on file. Rhinogard™ , APVMA: 49679, Registered to Zoetis Australia Pty Limited
2. The MSD Veterinary Manual (9th edition)(2008). www.msdvetmanual.com
3. MLA, Controlling BRD in feedlot cattle, FL06, 2001
4. Bovilis MH+IBR Field Trials: 20019:001. MSD Data on file

Why vaccinate for calf scours?

The risk of scours is high.

The pathogens that cause calf scours are everywhere.

Table showing prevalance of scours pathogens on New Zealand dairy farms

Why Rotavec Corona?

The gold-standard for the prevention of scours.

Rotavec Corona is the gold-standard for the prevention of scours.

Table comparing Rotavec Corona attributes with Competitor Products 

Increases antibodies in colostrum and milk

Calves are born without antibodies to fight infection. They rely completely on high-quality colostrum for protection against scours-causing pathogens.

It is critical that calves receive enough of the right antibodies in colostrum, and then in transition milk, to reduce their risk of scours.

Rotavec Corona significantly elevates neutralising antibodies in colostrum and milk for at least 28 days post-calving3

Graphs showing increased rotavirus, coronavirus and E.coli antibody concentration in colostrum and milk

 

Boosts levels of both G6 and G10 antibodies

Research shows Rotavec Corona vaccination boosts levels of both G6 and G10 antibodies.4

Graph of Virus Neutralising antibodies for Rotavirus serotype G6 &G10 in Rotavec Corona vs non-vaccinated cows

Cross-protection

Cows vaccinated with a single serotype produce antibodies to all serotypes to which they have had prior exposure. This response has been demonstrated by numerous researchers5,6,7 and is also observed with other viruses that have marked antigenic variability such as influenza.

Reduces environmental contamination.

Faeces from calves fed colostrum from Rotavec Corona vaccinated cows contain less virus. This results in reduced environmental contamination and less likelihood of virus spread to uninfected calves.4

Illustration of comparatively less virus and environmental contamination in Rotavec Corona calves

What you need to know

Health risks & diseases

icons8 ok 50

Thanks for contacting us.

Your message has been received. We will endeavour to reply to your enquiry within 2 working days. 

If your enquiry is urgent please contact us on 0800 800 543

Close
Close

Contact us

{{contactForm.fieldErrors.Message}}
{{contactForm.fieldErrors.Email}}
{{contactForm.fieldErrors.Recaptcha}}

Or call us

0800 800 543